NORTH WALES, Pa. — Teva Pharmaceuticals on Wednesday announced the introduction and availability of dexmethylphenidate hydrochloride extended-release capsules, CII, in 15-mg and 30-mg strengths. This product is AB rated and bioequivalent to Focalin XR extended-release capsules, CII.
With the addition of these two new strengths, Teva now offers dexmethylphenidate HCl extended-release capsules, CII in 15-mg, 30-mg and 40-mg.
"Our customers count on Teva for a continuous supply of new generic products,” stated Maureen Cavanaugh, SVP U.S. generics sales and marketing. "We are pleased to offer these two new strengths of Dexmethylphenidate HCl Extended-Release Capsules to our customers and patients."